PRPeter P. Robinson

Peter P. Robinson

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Peter P. Robinson has a total of 39 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Mannose-6-phosphate facilitates early peripheral nerve regeneration in thy-1-YFP-H mice

    by A.J. Harding, C.R. Christmas, M.W.J. Ferguson, A.R. Loescher, P.P. Robinson, F.M. Boissonade


  • Open Access

    Temporal mismatch between pain behaviour, skin Nerve Growth Factor and intra-epidermal nerve fibre density in trigeminal neuropathic pain

    by Laura J Evans, Alison R Loescher, Fiona M Boissonade, Simon A Whawell, Peter P Robinson, David Andrew

    Background: The neurotrophin Nerve Growth factor (NGF) is known to influence the phenotype of mature nociceptors, for example by altering synthesis of neuropeptides, and changes in NGF levels have been implicated in the pathophysiology of chronic pain conditions such as neuropathic pain. We have tested the hypothesis that after partial nerve injury, NGF accumulates within the skin and causes ‘pro-nociceptive’ phenotypic changes in the remaining population of sensory nerve fibres, which could underpin the development of neuropathic pain. Results: Eleven days after chronic constriction injury of the rat mental nerve the intra-epidermal nerve fibre density of the chin skin from had reduced from 11.6 ± 4.9 fibres/mm to 1.0 ± 0.4 fibres/mm; this slowly recovered to 2.4 ± 2.0 fibres/mm on day 14 and 4.0 ± 0.8 fibres/mm on day 21. Cold hyperalgesia in the ipsilateral lower lip was detectable 11 days after chronic constriction injury, although at this time skin [NGF] did not differ between sides. At 14 days post-injury, there was a significantly greater [NGF] ipsilaterally compared to contralaterally (ipsilateral = 111 ± 23 pg/mg, contralateral = 69 ± 13 pg/mg), but there was no behavioural evidence of neuropathic pain at this time-point. By 21 days post-injury, skin [NGF] was elevated bilaterally and there was a significant increase in the proportion of TrkA-positive (the high-affinity NGF receptor) intra-epidermal nerve fibres that were immunolabelled for the neuropeptide Calcitonin Gene-related peptide. Conclusions: The temporal mismatch in behaviour, skin [NGF] and phenotypic changes in sensory nerve fibres indicate that increased [NGF] does not cause hyperalgesia after partial mental nerve injury, although it may contribute to the altered neurochemistry of cutaneous nerve fibres.


  • Outcomes of Trigeminal Nerve Repair

    by Peter P. Robinson, Keith G. Smith, Søren Hillerup

  • Open Access

    Correlation of Nav1.8 and Nav1.9 Sodium Channel Expression with Neuropathic Pain in Human Subjects with Lingual Nerve Neuromas

    by Emma V Bird, Claire R Christmas, Alison R Loescher, Keith G Smith, Peter P Robinson, Joel A Black, Stephen G Waxman, Fiona M Boissonade

    Background: Voltage-gated sodium channels Nav1.8 and Nav1.9 are expressed preferentially in small diameter sensory neurons, and are thought to play a role in the generation of ectopic activity in neuronal cell bodies and/or their axons following peripheral nerve injury. The expression of Nav1.8 and Nav1.9 has been quantified in human lingual nerves that have been previously injured inadvertently during lower third molar removal, and any correlation between the expression of these ion channels and the presence or absence of dysaesthesia investigated. Results: Immunohistochemical processing and quantitative image analysis revealed that Nav1.8 and Nav1.9 were expressed in human lingual nerve neuromas from patients with or without symptoms of dysaesthesia. The level of Nav1.8 expression was significantly higher in patients reporting pain compared with no pain, and a significant positive correlation was observed between levels of Nav1.8 expression and VAS scores for the symptom of tingling. No significant differences were recorded in the level of expression of Nav1.9 between patients with or without pain. Conclusions: These results demonstrate that Nav1.8 and Nav1.9 are present in human lingual nerve neuromas, with significant correlations between the level of expression of Nav1.8 and symptoms of pain. These data provide further evidence that changes in expression of Nav1.8 are important in the development and/or maintenance of nerve injury-induced pain, and suggest that Nav1.8 may be a potential therapeutic target.


  • Histomorphometric changes in repaired mouse sciatic nerves are unaffected by the application of a scar-reducing agent

    by Wei Cheong Ngeow, Simon Atkins, Claire R. Morgan, Anthony D. Metcalfe, Fiona M. Boissonade, Alison R. Loescher, Peter P. Robinson

    Microsurgical repair of transected peripheral nerves is compromised by the formation of scar tissue and the development of a neuroma, thereby limiting the success of regeneration. The aim of this study was to quantify histomorphometrically the structural changes in neural tissue that result from repair, and determine the effect of mannose-6-phosphate (M6P), a scar-reducing agent previously shown to enhance regeneration. In anaesthetised C57-black-6 mice, the left sciatic nerve was sectioned and repaired using four epineurial sutures. Either 100 was injected into and around the nerve repair site. A further group acted as sham-operated controls. After recovery for 6 weeks, the nerve was harvested for analysis using light and electron microscopy. Analysis revealed that when compared with sham controls, myelinated axons had smaller diameters both proximal and distal to the repair. Myelinated axon counts, axonal density and size all decreased across the repair site. There were normal numbers and densities of non-myelinated axons both proximal and distal to the repair. However, there were more Remak bundles distal to the repair site, and fewer non-myelinated axons per Remak bundle. Application of M6P did not affect any of these parameters.lL of 600 mM M6P (five animals) or 100 lL of phosphate-buffered saline (placebo controls, five animals


    • 1 January 2009
      • Vol. 23  (1) , 65-72

    Immunohistochemical analysis of the purinoceptor P2X7 in human lingual nerve neuromas.

    by Claire R Morgan, Emma V Bird, Peter P Robinson, Fiona M Boissonade

    Recent evidence suggests that the purinoceptor P2X7 may be involved in the development of dysesthesia following nerve injury, therefore, the aim of the present study was to investigate whether a correlation exists between the level of P2X7 receptor expression in damaged human lingual nerves and the severity of the patients' symptoms. Neuroma-in-continuity specimens were obtained from patients undergoing surgical repair of the damaged lingual nerve. Specimens were categorized preoperatively according to the presence or absence of dysesthesia, and visual analog scales scores were used to record the degree of pain, tingling, and discomfort. Indirect immunofluorescence using antibodies raised against S-100 (a Schwann cell marker) and P2X7 was employed to quantify the percentage area of S-100 positive cells that also expressed P2X7. P2X7 was found to be expressed in Schwann cells of lingual nerve neuromas. No significant difference was found between the level of P2X7 expression in patients with or without symptoms of dysesthesia, and no relationship was observed between P2X7 expression and VAS scores for pain, tingling, or discomfort. No correlation was found between P2X7 expression and the time between initial injury and nerve repair. These data show that P2X7 is expressed in human lingual nerve neuromas from patients with and without dysesthesia. It therefore appears that the level of P2X7 expression at the injury site may not be linked to the maintenance of neuropathic pain after lingual nerve injury.


  • A prospective, quantitative study on the clinical outcome of inferior alveolar nerve decompression and neurolysis

    by P.P. Robinson, J.M. Yates, K.G. Smith

    Aim:  The management of persistent anaesthesia or dysaesthesia following damage to the inferior alveolar nerve is difficult, and the benefit of interventions is often unclear. We have evaluated the outcome of inferior alveolar nerve decompression and neurolysis in a series of 25 patients, with injuries usually sustained during third molar removal, who had poor spontaneous recovery.Materials and methods:  The mean age at surgery was 45 years, and most patients were female (21 patients). The mean period between the initial injury and decompression was 28 months, and we assessed the final outcome at 1 year or more after decompression. Assessment included the responses to a series of standard questions, completion of visual analogue scales (VAS) and sensory tests.Results:  We found that after decompression fewer patients reported pain, and VAS scores were significantly reduced for the level of tingling. Patients also reported better subjective levels of sensation after decompression, and sensory tests confirmed small but significant improvements. The median subjective value of the operation was assessed by patients as 7 (range 0–10).Conclusions:  These data show that inferior alveolar nerve decompression results in significant reductions in the level of dysaesthesia and improvements in sensation. However, as the overall level of improvement is small, and some patients do not improve, the procedure should only be offered to patients who are significantly affected by their symptoms.


  • Interleukin‐10 reduces scarring and enhances regeneration at a site of sciatic nerve repair

    by Simon Atkins, Alison R. Loescher, Fiona M. Boissonade, Keith G. Smith, Nick Occleston, Sharon O’kAne, Mark W. J. Ferguson, Peter P. Robinson

    Abstract  Axonal regeneration at a site of peripheral nerve repair can be impeded by the formation of scar tissue, which creates a mechanical barrier and initiates the development of multiple branched axonal sprouts that form a neuroma. We have investigated the hypothesis that the application of a scar‐reducing agent to the nerve repair site would permit better axonal regeneration. In anaesthetised C57 Black‐6 mice, the left sciatic nerve was sectioned and immediately re‐approximated using four epineurial sutures. In five groups of eight mice, we injected transforming growth factor‐β3 (50 or 500 ng), interleukin‐10 (IL‐10) (125 or 500 ng), or saline into and around the repair site, both before and after the nerve section. Another group of eight animals acted as sham‐operated controls. After 6 weeks, the outcome was assessed by recording compound action potentials (CAPs), measuring collagen levels using picrosirius red staining, and counting the number of myelinated axons proximal and distal to the repair. CAPs evoked by electrical stimulation distal to the repair were significantly smaller in all repair groups except for the low‐dose IL‐10 group, where they were not significantly different from that in controls. The area of staining for collagen had significantly increased in all repair groups except for the low‐dose IL‐10 group, which was not significantly different from that in controls. The myelinated fibre counts were always higher distal to the repair site, but there were no significant differences between groups. We conclude that administration of a low‐dose of IL‐10 to a site of sciatic nerve repair reduces scar formation and permits better regeneration of the damaged axons.